- Delayed again: Canada delays pricing reform until January 2022
- The Access Consortium’s new strategic plan
- The WHO highlights risks of AI in healthcare
- Senate Finance Chair share recommendations for US drug pricing
Given the overlap in Joint Clinical Assessment (JCA) and national-level HTA timelines, manufacturers...
Read moreIntroduction Announced in the 2025 NHS 10-year plan, the National HealthTech Access Programme (NHAP)...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.
Get in touch